Slingshot members are tracking this event:

Agios Pharma (AGIO) data from Phase 1 trial of AG-120 underwhelms investors

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

CELG Community voting in process

Additional Information

Additional Relevant Details AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein, and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 09, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Data, Ag-120, Idh1 Inhibitor, Glioma, Sarcoma, Liver Tumor